Stockscreener 앱 받기
17.73
0.11%
0.0451
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - MarketScreener
Is Bicara Therapeutics Inc. stock a buy before product launchesJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Bicara stock jumps after FDA grants breakthrough therapy status By Investing.com - Investing.com Nigeria
Bicara stock jumps after FDA grants breakthrough therapy status - Investing.com
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation - MarketScreener
Bicara Therapeutics climbs after FDA's 'breakthrough' tag for cancer therapy - TradingView
Why Bicara Therapeutics Is Rising In Pre-market? - Nasdaq
FDA grants breakthrough therapy status to Bicara’s cancer drug - Investing.com
Bicara Therapeutics Announces Ficerafusp Alfa Granted - GlobeNewswire
Is Bicara Therapeutics Inc. stock resilient to inflationTrade Analysis Summary & Short-Term High Return Strategies - newser.com
How to build a custom watchlist for Bicara Therapeutics Inc.Weekly Trade Recap & Intraday High Probability Alerts - newser.com
Ivan Hyep Sells 6,415 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Insider David Raben Sells 22,000 Shares - MarketBeat
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares By Investing.com - Investing.com Australia
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 18,244 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $715,176.00 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 10,900 Shares - MarketBeat
Ivan Hyep Sells 6,514 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 5,627 Shares of Stock - MarketBeat
Risk adjusted return profile for Bicara Therapeutics Inc. analyzedJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Can Bicara Therapeutics Inc. stock resist sector downturnsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares By Investing.com - Investing.com South Africa
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Bicara therapeutics president Cohlhepp sells $911k in shares By Investing.com - Investing.com Canada
Day 8 of Gains Streak for Bicara Therapeutics Stock with 70% Return (vs. 4.3% YTD) [10/7/2025] - Trefis
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Statistical indicators supporting Bicara Therapeutics Inc.’s strengthGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
What drives Bicara Therapeutics Inc stock priceVWAP Trading Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Is Bicara Therapeutics Inc. stock reversal real or fakeJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Key metrics from Bicara Therapeutics Inc.’s quarterly dataQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Bicara Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Bicara Therapeutics files for mixed shelf offering of up to $400 millionSEC filing - MarketScreener
How to read the order book for Bicara Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Stifel maintains Buy on Bicara stock with $47 target - MSN
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen - Investing.com South Africa
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen By Investing.com - Investing.com Nigeria
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 5.5%Here's Why - MarketBeat
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating - TipRanks
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
What analysts say about Bicara Therapeutics Inc stockTrend Following Strategies & Big Profit Small Investment - earlytimes.in
Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.25 - Defense World
1.09%
자본화:
|
볼륨(24시간):